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A B S T R A C T
Mass drug administration utilising a single oral dose of 40 mg/kg of praziquantel (PZQ) has been
endorsed and advocated by theWorld Health Organisation (WHO) for the global control and elimination
of schistosomiasis. However, this strategy is failing primarily because the drugs are not getting to the
people who need them themost. The current global coverage is 20%, the drug compliance rate is less than
50%, and the drug efﬁcacy is approximately 50%. Thus in reality, only about 5% of the reservoir human
population is actually receiving intermittent chemotherapy. Despite claims that more of the drug will
soon be made available the current strategy is inherently ﬂawed and will not lead to disease elimination.
We discuss the many practical issues related to this global strategy, and advocate for an integrated
control strategy targeting the life cycle and the most at-risk. Moreover, we discuss how an integrated
control package for schistosomiasis should ﬁt within a larger integrated health package for rural
and remote villages in the developing world. A holistic health system approach is required to achieve
sustainable control and ultimately disease elimination.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).This is an open access artic1. Introduction
Schistosomiasis is a neglected tropical disease caused by blood
ﬂukes of the genus Schistosoma. It afﬂicts approximately 240million
individuals in the tropics and subtropics, causing roughly 70million
disability-adjusted life years.1,2 Schistosomiasis is the third most
devastating tropical disease globally and is a major cause of
morbidity andmortality inAfrica, SouthAmerica, the Caribbean, the
Middle East, and Asia. 1,2 More than 78 countries are affected, and
nearly 800 million people are exposed to the disease.1,2
We are presently conducting a clinical trial in Northern Samar,
the Philippines, on the integrated control of schistosomiasis.3
During the course of the trial, we have been treating patientswith a
single oral dose of 40 mg/kg PZQ, but noted rapid reinfection rates
in an area of moderate zoonotic transmission. In the Philippines,
the National Department of Health is utilizing a single oral dose of
40 mg/kg of PZQ to treat endemic communities empirically for
schistosomiasis, during annual mass drug administration (MDA)
campaigns. This approach has been endorsed and advocated by the
WHO for the global control of schistosomiasis.4 However, this
strategy is not working due to poor drug coverage, poor drug
compliance, and many other factors.5 We discuss the many
practical issues related to this global strategy and advocate for an
integrated control program targeting the life cycle and the most at
risk. Moreover, we discuss in detail the practical steps required to
achieve sustainable control.
2. Current Global Strategy–MDA with single oral dose of
40 mg/kg of PZQ
Numerous studies have claimed that ‘preventive chemothera-
py’ utilising 40 mg/kg of PZQ given annually can signiﬁcantlyhttp://dx.doi.org/10.1016/j.ijid.2016.09.023
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).reduce the prevalence and intensity of infection, and control
morbidity in the long term.6,7 However, PZQ is not 100% curative in
killing adult worms, cannot kill migrating schistosomulae or the
early stages of the disease, and does not prevent reinfection.8,9 It
has been stated that MDAmay reduce population immunity in the
long term and if stopped can lead to large rebounds in egg
counts.10,11 Moreover, multiple rounds of MDA among school
children have resulted in a reduced efﬁcacy of PZQ which poses a
threat to global MDA programs.12
Parasitological cure depends on the treatment dose. In the early
1980s and again in 2011, WHO, in an attempt to optimize PZQ use
for the treatment of schistsomiasis, launched a series of multi-
country trials, comparing the efﬁcacy and safety of 40 mg/kg
versus 60 mg/kg in schistosome infected patients in Asia, Africa
and the Americas.13 In these clinical trials, the 40 mg/kg dose was
found to be effective (92% cure rate) and better tolerated than the
higher 60 mg/kg dose.13 However, a recent systematic review and
meta-analysis of 52 clinical trials showed that, when compared
with placebo, a dosage of 30-60 mg/kg PZQ produced a cure rate of
76% (range from 67-83%) for human schistosomiasis.14 No
signiﬁcant differences in cure rates were found among subjects
infected with S. haematobium, S. japonicum or S. mansoni. The cure
rate of the drug at 40 mg/kg (which is the current dose
recommended by the WHO) was 52% (range from 49-55%),
compared with 91% (range from 88%-92%) when dosages were
increased to 60, 80, 100 mg/kg, divided into two ormore doses.14 A
recent pharmacokinetic study, on a paediatric population in Africa,
has recommended a higher dosage (>60 mg/kg) to achieve
therapeutic cure in young children.15
Inadequate treatment coverage is a serious obstacle for MDA
implementation. In 2001, the 54th World Health Assemblyciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Figure 1. Percentage of global target population reached with ‘preventive chemotherapy’ for schistosomiasis control. The WHO reported that the global MDA coverage was
approximately 20% in 2014.17 It is assumed the compliance to free treatment is 50% and that the efﬁcacy of PZQ at the single oral dose of 40 mg/kg is 50%.14
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to combat schistosomiasis with the goal of achieving a drug
coverage rate of 75-100% among school-aged children at risk of
morbidity by 2010.7,16 However, the target coverage was not
attained according to the 65th World Health Assembly7,16 In 2014,
the global coverage was reported to be 20.74%.17 Clearly such a
coverage ratewill not halt the transmission of the disease or lead to
disease elimination (Figure 1). Much has been written about the
beneﬁts of MDA in order to secure large amounts of donor funding,
but the operationalization of such programs has been grossly
underestimated. In some of the poorest countries in the world,
where MDA is taking place, the health systems are weak,
understaffed and poorly resourced.16,17 Is it, therefore, realistic
to expect such countries to achieve >75% drug coverage rates?
Most donors are willing to donate the drugs but few are willing to
ensure safe delivery and consumption (e.g. directly observed
treatment - DOT). Unless we do a better job ‘on the ground’ with
the coordination of local control activities this strategy will surely
falter. WHO and international agencies must take a more active
role in operational management of MDA delivery.
Low patient compliance for free medication is another MDA
impediment. Drug compliance is very low with many countries
reporting<50% compliance.5,17 It has been reported that up to 80%
of those who ultimately take the drug suffer from transient side-
effects such as dizziness, syncope, vomiting and diarrhoea.5 Once
the side-effects are observed and reported by others in the
community, compliance quickly drops. Again if treatment is left in
the hands of local untrained medical staff, compliance will surely
reduce. Many of the current MDA programs in Africa utilise unpaid
volunteers with no health background to deliver MDA to patients
for schistosomiasis.5,17 If such a person came to your door, would
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Figure 2. Key elements of an integrated control strategy required for the global
sustainable control of schistosomiasis leading to disease elimination. Note:
PZQ = praziquantel; ART = artemether.you take a drug from someone you do not know, who is untrained,
for a disease you are not familiar with, with no conﬁrmation of
your infection status? Clearly not, thus the poor compliance rate
globally. Getting the drugs from the pharmaceutical industry is one
issue, but ensuring safe delivery and consumption is another issue,
that to date has been grossly underestimated and uncoordinated.17
The reported coverage and compliance rates are questionable
given they are derived from internal evaluation reports. Interna-
tional and national control teams involved in MDA campaigns are
under enormous pressure to show tangible results for the millions
of dollars invested. Thus, they are clearly biased in the reporting of
their coverage rates. Moreover, there is typically a mismatch in
what is reported by the service providers for successful treatment
(coverage) and who actually swallows the drug (compliance). It is
well known that many who are offered the drug (e.g. put in their
hands or mouth) simply throw it away or keep for later use when
they feel sick. Moreover, it is not uncommon for service providers
to rely on family members to administer drugs to their relatives
who miss the MDA.
3. New global strategy–split oral dose of 60 mg/kg
PZQ + integrated control
What is the new global strategy based on? The new global
strategy is not based on theoretical modelling but on our practical
ﬁrsthand experience in participating in ﬁeld-based schistosomiasis
control programs over the past thirty years. What is outlined can
only be achieved if members of the core control team (e.g., national
and international healthcare providers) are committed to live and
work in the endemic area for extended periods of time (months).
On the ground planning, coordination, and daily supervision are
vital to ensure local support, community engagement, drug
coverage and patient compliance.5 Key elements of the integrated
control strategy required to achieve disease elimination are
illustrated in Figure 2. There are twomajor transmission pathways
in the schistosome life cycle that can be targeted by control
programs: the parasites’ path fromhumans (the deﬁnitive hosts) to
snails (the intermediate hosts), and their path from snails to
humans.18 Mass PZQ treatment acts only on the transmission
pathway from humans to snails and only for as long as treatment is
given. A multifaceted integrated approach targets both pathways:
complementing treatmentwith snail control, health education and
water, sanitation and hygiene (WASH).
3.1. Target population
Who should be targeted for integrated control? Presently MDA
campaigns are largely given to school children.7 The advantage of
this strategy is that a segment of the at-risk population can easily
be reached for annual mass treatment. The disadvantage is that
remote communities, and other at-risk populations are largely left
untreated.7 Given the clumped distribution of the disease these
‘wormy’ individuals are responsible for continued transmission.
Thus, ‘preventive chemotherapy’ has limited impact on reducing
the reservoir of infection. Future control efforts need to focus on
[(Figure_3)TD$FIG]
Figure 3.Global distribution of schistosomiasis showing themost at-risk populationswithin Africa. Highly endemic countries (dark red) are proposed to be the focus of future
integrated control efforts.2
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50% and high-risk individuals (e.g. ﬁshermen, farmers) within
those communities. Is trying to achieve disease elimination in a
low endemic area (e.g. SCORE project7 in Zanzibar with a human
prevalence<10%) a wise investment of limited donor funding?We
believe donor funding should go to those who need it the most.
However, the caveat is that those who need it the most, live in
areas that are very poor and hard to reach. Moreover, they are
typically less educated and are less likely to comply to health
education and treatment. These are also precisely the areas where
control staff do not want to visit for annual MDA. Figure 3 below
shows the endemic countries in Africa where the human
prevalence is greater than 50%.2 One of the highly endemic
countries is Mozambique. To date this country has largely been
ignored by donor agencies and the obvious question is why?
3.2. Political support & Community engagement
In order for integrated control to be successful, there must be
support at the national, regional, and provincial level, but this is
not enough.5,18 The rate limiting step in global control is at the
district/municipal level. Typically there is a district doctor/clinical
ofﬁcer who is responsible for coordinating control activities with a
team of community health workers (e.g., 10-30 female nurses and/
or midwifes). They are typically responsible for 30-50 villages and
an overall population of approximately 30,000-50,000 residents. If
the district doctor is active and well respected in the community it
is likely that they will be able to convince the village chiefs/
captains of the importance of the work, with the assistance of
members of the control team (e.g., national and international staff).
However, if there is no district physician/clinical ofﬁcer or the
doctor is not engagedwith the community, then it is unlikely at the
onset that the proposed integrated control work will be possible.
Building relationships at the grassroots level is fundamental for the
sustainability of any community-based activity and this is well
documented.17 Most global MDA programs currently do not have
such a relationship, thus, are unlikely to be sustainable. Integrated
control requires fostering long term community relationships.5
If communities agree to support the integrated control
initiative they will want to know what else they will get out ofit. Will free treatment be provided? If so, how often will it be
provided and who will get it? Will they be paid for their work if
required towork on the project?What other health serviceswill be
provided in addition to schistosomiasis control? The use of unpaid
volunteers with little or no training is common practise in current
MDA programs in Africa.7 However, in the integrated control
model, proposed trained staff must be paid a part-time salary for
typically 2-3 three months per year depending on the activities
they are involved in (e.g., driver, stool/urine collector, slide reader,
molluscide sprayer, nurse, data entry etc.).
3.3. Diagnostics
In order to achieve a high compliance rate for treatment,
patients will want to know if they are egg positive or not (e.g.,
infected). This is absolutely critical for sustainable control leading
to elimination. We realise the cost, time, and technological skills
required to read the stool and/or urine slides, but this is a non-
negotiable component of integrated control. ‘Preventive chemo-
therapy’ is failing globally due in part to poor drug compliance
rates for free treatment.With appropriate community engagement
most residents will provide at least one stool or urine sample for
diagnostic assessment, and if found positive are more likely to
comply with treatment.17
Several advances (e.g., antibody/antigen/DNA tests) have been
made for the diagnosis of schistosomiasis. However, the technolo-
gy that can be deployed in rural and remote communities is limited
given many communities struggle to have regular power supply
and water. In Northern Samar, where we are presently working,
there are scheduled power outages every week lasting an entire
day and typically 1-2 unexpected outages per week.3 Thus, the
diagnostic strategy selected and deployed, must use low technol-
ogy and be able to be administered by an unskilled local labour
force. For intestinal schistosomiasis the Kato-Katz thick smear
stool examination (Figure 4), and urine samples for detection of S.
haematobium, are still the gold standard for ﬁeld application. It
cannot be taken for granted that local microscopists are able to
read stool and/or urine slides even after receiving the appropriate
training. Quality control measures (e.g., 10% of all slides read
blindly by an experienced microscopist),3 are vital to ensure a
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Figure 4. National and local staff members preparing Kato-Katz thick smear stool
slides for microscopic examination in the ﬁeld.
Editorial / International Journal of Infectious Diseases 54 (2017) 130–137 133reliable diagnosis and reported prevalence/cure rates. Through our
work, we noticed considerable inter/intra-examiner bias in the
reading of Kato-Katz stool slides.3 Staff that are recruited for this
purpose must be tested and if their skills are insufﬁcient, must not
be hired, or retrained. Daily supervision is required by the head
microscopist and quality assurance protocols must be in place.
3.4. Treatment–Annual 60 mg/kg PZQ + 6 mg/kg ART
Preventive chemotherapy with a single oral dose of 40 mg/kg of
PZQ is inadequate to control and eliminate schistosomisis.16,17,19
Rapid reinfection rates are occurring globally and there is now
evidence of drug resistance.17 As mentioned, the efﬁcacy of the
drug is approximately 50% due to the drugs inability to kill
migrating schistosomula and the early stages of the disease. Thus,
we recommend annual DOT treatment with a split dose of 60 mg/
kg of PZQ to kill existing adult worms and 6 mg/kg of artemether to
kill the early stages of the disease in those who have a conﬁrmed
diagnosis. However, to do this on a large scale repeat visits to a
single village in the same year is logistically impossible, given the
total number of villages to be treated and the associated logistical
cost.
Artemether (ART) (and other artemisinin derivatives), which
comes from the leaves of the Chinese medicinal plant Artemisia[(Figure_5)TD$FIG]
Figure 5. A. Mass drug administration in Northern Samar, The Philippines. B. Younannua, is effective against juvenile schistosomes during the ﬁrst
21 days of infection in both animals and humans.20–22 The dose
required (i.e., 6 mg/kg) is lower than that required to treat malaria,
thus given once per year with PZQ, it is unlikely to lead to the
selection of ART-resistant Plasmodium falciparum. The combination
of PZQ-ART given once per year should improve cure rates, thus
reducing the reservoir pool of infected individuals needed to halt
transmission.20–22 It is noteworthy that to date no clinical trial has
speciﬁcally looked at using PZQ-ART once per annum, but other
treatment regimens using this drug combination have proven to be
safe and effective, leading to higher cure rates.20–22 Thus, what is
now proposed would appear appropriate as part of an integrated
control package. Our overall goal would be to have an annual drug
compliance rate (e.g., DOT for diagnosed conﬁrmed cases) of at
least 80%, in over 90% of the villages with a human prevalence over
50%, within the next ten years. We believe this is a realistic goal if
appropriate funding can be secured from national governments
and international donors.
Advanced cases for the disease need appropriatemedical and/or
surgical follow-up (Figure 5). Nomention of this is stated in current
MDA campaigns and this raises serious ethical considerations.23
Clearly we have a moral and ethical duty to assist such patients
(e.g. <5% of total cases) that will be encountered in the
community.24 Prior to the commencement of integrated control,
it is proposed that the Ministry of Health would sign a written
agreement that indigent patients can be sent for appropriate
referral, and that all medical expenses will be covered by the
government’s health-care scheme.23 The state/provincial govern-
ment should be lobbied to provide for local travel, and a modest
living allowance for the spouse or guardian while the patient is
undergoing treatment and recovery.23 This requires planning
before entering communities, as the needs are often overwhelming
for physicians. If the control team are committed to such
humanitarian efforts, this will strengthen relationships with the
community, which will likely improve patient and community
compliance, and aid in the sustainability of the control program. In
Northern Samar we have provided care not only for those with
advanced schistosomiasis but formany other surgical conditions.23
This was recognised and well received by both the provincial
government and the community residents, which contributed to
solidifying grass roots relationships. Moreover, as a service to the
communities under study, we provided primary-care during our
annual follow-up visits.23 The impact of such a service in terms of
community wellness and building community rapport, cannot be
underestimated. Unfortunately, this essential service is rarely, if
ever provided as a part of global health programs.23g patient who required surgery (splenectomy) for advanced schistosomiasis.24
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Schistosomes have coevolved with their molluscan intermedi-
ate hosts resulting in a well-balanced and highly efﬁcient means of
transmission. Each schistosome species infects a speciﬁc fresh-
water snail intermediate host - e.g., with S. mansoni this is
generally Biomphalaria glabrata (Americas) or B. pfeifferi (Africa);
with S. japonicum, it is Oncomelania hupensis hupensis in China and
Oncomelania hupensis quadrasi in the Philippines.25 The interme-
diate snail host has been targeted for control in order to break the
life-cycle of the disease. However, mollusciciding using niclosa-
mide has proven challenging given it is a known pollutant.25 As a
consequence, in Asia, targeted mollusciciding of identiﬁed ‘snail
hotspots’ (cercarial positive snail sites) have now become an
integral part of the national control program in China.25
It has recently been stated that the control of the snail
intermediate host is the missing link for elimination efforts in
Africa.26 However, we recently attended a Gates Foundation
meeting and were informed that the reason why it was not part of
current ‘preventive chemotherapy’ campaigns was that there are
very few people left in Africa who can correctly identify the snail
intermediate host. This is a serious obstacle for future integrated
control efforts, but not impossible to overcome. Control staff can be
retrained to correctly identify the snail host and historically
endemic snail habitats can be revisited. However, considerable
effort is required to correctly identify ‘snail hotspots’ for targeted
mollusciding.3 Local staff who are largely untrained and often
unmotivated, must be lead on the ground by a member of the
project leadership team who fully appreciates the importance of
this component of control. Without this operational leadership on
the ground, this essential component will not be achieved.
There is no question that this component will take time and
considerable effort in the ﬁeld. However, in Northern Samar with a
team of ten (Figure 6) we were able to cover approximately
3-4 villages per day.3 Each village typically had 2-4 endemic zones
ranging in size from0.5-1 squared kilometre. It is clearlynot possible
to spray the entire area given the size of the transmission zones, the
price of niclosamide, and the fact that niclosamide is a pollutant.
Hence, GPS identiﬁed ‘hotspots’ were targeted for mollusciding.
If the goal is to achieve disease elimination, this is a vital component
of integrated control that cannot be omitted. In the current global
MDA strategy, this component has been left out, thus another reason
why ‘preventive chemotherapy’ is inherently ﬂawed.
3.6. Health education
Health education is a further component of integrated control
that has again been neglected in the era of MDA. Clearly this
[(Figure_6)TD$FIG]
Figure 6. A. Snail intermediate host survey in an endemic barangay in Northern Samar
spraying.3impacts on drug coverage if the technical knowledge and expertise
is not available at the national, regional, state, district and most
importantly, the village level. Any lack of knowledge in delivery of
the drug will lead to a signiﬁcant drop in drug coverage. The rate
limiting step is at the village level and this is where most MDA
programs are failing. Poor understanding of the disease also leads
to reduced patient compliance to free treatment and risk taking
behaviour (e.g., exposure to endemic freshwater). If a patient
knows about the disease and knows that they are infected (e.g.,
conﬁrmed by diagnosis) they are more likely to comply with
treatment on an annual basis. A video-based health educational
intervention package for soil transmitted helminths (STHs) was
recently tested among school children in China and showed a 50%
reduction in the incidence rate and a signiﬁcant change in
behaviours.27,28 Clearly an educational package is needed on
many fronts as part of an integrated control strategy for
schistosomiasis.
3.7. WASH
Long-term schistosomiasis control will require improvements
to WASH, in order to break the life cycle of the disease. WASH
interventions are diverse, potentially including improvements in
water access (e.g., water quality, water quantity, and distance to
water), sanitation access (e.g., access to improved latrines, latrine
maintenance, and faecal sludge management), and hygiene
practices (e.g., handwashing before eating and/or after defecation,
water treatment, soap use, wearing shoes, and water storage
practices). Interventions often include multiple components while
also providing hygiene education. WASH access and practices are
generally associated with reduced odds of STH infection. Pooled
estimates from allmeta-analyses indicated at least a 33% reduction
in the odds of infection associated with individual WASH
practices.29 There are a number of low cost solutions (e.g., urine
diverting dry toilets), that are worth pursuing if funding permits.
However, the reality is that little funding is spent by national
governments on this poverty reduction initiative. Thus, local
communities, in partnership with donor agencies, will need to
make this essential intervention a priority.
3.8. Program evaluation
Annual program evaluation of the control work is critical for the
implementation and sustainability of integrated control, and again
this is lacking in most MDA programs. There is considerable
variation (e.g., ecological, political commitment etc.) from region
to region and from village to village. Each village will have
obstacles to overcome that must be monitored in an ongoing, the Philippines. B.GPS identiﬁcation of snail hotspots for future focal niclosamide
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while others will be more challenging to motivate, with a
multitude of reasons. As mentioned, success is largely based on
village cooperation and the motivation of the control team. If a
village will not comply despite concerted efforts to convince them
(e.g., multiple meetings with the village and local government
leaders), it will have to be omitted from the control program. There
is simply a ﬁnite amount of ﬁnancial resources that have to be well
spent. It is also demoralizing for the control staff to work in a
community where they feel their efforts are not valued or
appreciated. In Northern Samar we have had barangays that
would simply not comply despite our best efforts to persuade
them.3 The mayor met with the barangay captains and the health
workers, but still they refused to participate, hence the hard
decision wasmade to omit them from future control efforts. Tough
decisions such as these rise periodically and require ongoing
monitoring and evaluation.
3.9. Financing global integrated control
Neglected tropical diseases are in reality a low priority formany
developing nations who struggle to pay healthcare salaries and
keep tertiary-care hospitals functioning. Many of these countries
are crippled by the allocation of constrained resources towards
HIV, malaria and TB control, and periodic epidemics, thus limited
or negligible resources are left for NTDs. However, WHO andmany
senior academics have openly stated that by 2020, schistosomiasis
will be eliminated from many countries, thus the disease is
deemed a low priority.7 Why spend money on a disease that is
close to elimination? In the Philippines, WHO has stated that
schistosomiasis is close to elimination, thus the Secretary of Health
stated at a recent schistosomiasis conference that the disease was
no longer a public health priority. However, schistosomiasis is not
close to elimination in the country and it is indeed a major public
health problem in the Visayas (e.g., Samar, Leyte) and Mind-
anao.3,17 This same scenario is true for many African nations. In
sum, in the developing world most countries view NTDs as a low
priority thus limited national support will be provided for
integrated control efforts.
International donors have limited understanding of the
complex life cycle of schistosomes and the coordination of disease[(Figure_7)TD$FIG]Integrat
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Figure 7. Proposed low cost integrated health package for rural and remote communitie
deworming program.control programs on the ground.5,7,16 International donors and
foreign governments (i.e., USAID andDFID, using taxpayers dollars)
have recently given large sums of money for MDA programs
(primarily in Africa) that are typically for 3-5 years in duration.
However, such funds will have little or no impact given the control
strategy deployed (MDA), duration of the project, and that NGOs
such as Family Planning International (FHI), and Christian Blind
Mission (CBM) are coordinating this work on the ground using
‘trained non-healthcare personnel’ to deliver the drugs.7 The NGOs
have local logistical expertise but have little or no history of
working on NTDs.7 Clearly long-term (5-10 years) funding is
required for integrated control and the package delivered by
health-care teams with disease speciﬁc expertise. However, one
major donor informed us ‘‘everyone knows that long-term funding
is required for integrated control, and that this is the way forward
but no one will fund it. People want quick returns on their
investments and to see the numbers’’.
4. Conclusions
It is becoming increasingly clear that the global sustainable
control of schistosomiasis will require an integrated, inter-
sectorial approach that goes beyond deworming. Table 1 illustrates
some of the operational inputs and expected outputs of ‘mass drug
administration’ versus ‘integrated control’ required for the global
elimination of schistosomiasis. Clearly integrated control is the
way forward but it will require a long-term ﬁnancial investment
that must largely be supported by national governments. Is it
realistic to believe that a disease that has been endemic in many
countries for over 2,000 years can be eliminated by one drug in 3-5
years? Clearly the 2020 and the 2030 elimination goals put forward
are unrealistic and undermining global control efforts.7 It is time to
set a new agenda for the global elimination of schistosomiasis over
the next century.
The new global strategy proposed for the elimination of
schistosomiasis is just one part of the ‘integrated health package’
required for rural and remote communities in the developing
world where most of the ‘bottom billion’ struggle on less that one
dollar per day (Figure 7). Limited donor funding needs to be better
spent on sustainable development initiatives that addresses
poverty and the life cycle of these diseases. Ultimately theseed Health
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s in the developing world. Note: Integrated control for schistosomiasis is part of the
Table 1
Operational inputs and expected outputs of Mass Drug Administration versus
Integrated Control for the global elimination of schistosomiasis
Inputs Mass Drug
Adminstration
Integrated
Control
Logistics Minimal Extensive
Pharmaceutical industy
involvement
Extensive Minimal
National Drug Supply Chains Required Required
Baseline Assesement Minimal
or none
Extensive
Program Evaluation Minimal
or none
Extensive
Operational cost Minimal Moderate
or extensive
Operational coordination Minimal Extensive
Impact on Prevalence Moderate Extensive
Impact on Incidence Minimal Moderate
to extensive
Impact on Morbidity Short-term Long-Term
Use of unpaid volunteers Moderate
or extensive
None
Use of skilled expertise Minimal Extensive
Diagnostics Minimal
or none
Extensive
Project Commitment Short-term
(e.g. 3-5 years)
Long-term
(>5 years)
Political Commitment Short-term Long-term
Sustainability Short-lived Long-term
Editorial / International Journal of Infectious Diseases 54 (2017) 130–137136endemic communities will have to lift themselves out of poverty
though cooperatives and microenterprise.
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